Don't Miss


Just Published: Malignant Melanoma: PD-1 inhibitors revolutionise treatment is a comprehensive report with insights from 12 leading US and European KOLs offering their latest views on current and late-stage pipeline products, why and when they would prescribe them, and the factors likely to affect their future positioning and competitiveness.Learn more.

AbbVie boosts annual earnings forecast as Humira sales surge 17.5 percent in Q3